Published Date: 31 Oct 2025
The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.
Read Full News1.
Ultrasonography of hepatocellular carcinoma: From diagnosis to prognosis
2.
US Counties Suffered Significantly from a Lack of Psychiatric Care.
3.
Research suggests peer support may lower depression, stress among cancer patients in low-resource settings
4.
Sydney researchers identify new tools to improve cancer diagnosis and treatment.
5.
Cancer Diagnoses Still Lagging; Cancer and Family Health; New Type of Lung Cancer
1.
Genetic Screening: A Game Changer in Cancer Prevention
2.
Precision Oncology: How Personalized Medicine is Transforming Cancer Treatment
3.
Revolutionizing Oncology: AI in Radiology, Machine Learning in Pathology, and Deep Learning for Cancer Detection
4.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
5.
Revolutionizing Oncology: Pharmacometric Models in Personalized Cancer Drug Development
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
2.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
3.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation